CL2016002020A1 - Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor - Google Patents

Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor

Info

Publication number
CL2016002020A1
CL2016002020A1 CL2016002020A CL2016002020A CL2016002020A1 CL 2016002020 A1 CL2016002020 A1 CL 2016002020A1 CL 2016002020 A CL2016002020 A CL 2016002020A CL 2016002020 A CL2016002020 A CL 2016002020A CL 2016002020 A1 CL2016002020 A1 CL 2016002020A1
Authority
CL
Chile
Prior art keywords
plp
cofactor
erythrocytes
encapsulate
envelope
Prior art date
Application number
CL2016002020A
Other languages
English (en)
Spanish (es)
Inventor
Yann Godfrin
Vanessa Bourgeaux
Fabien Gay
Thomas Cortese
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma filed Critical Erytech Pharma
Publication of CL2016002020A1 publication Critical patent/CL2016002020A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01005—Tyrosine transaminase (2.6.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
CL2016002020A 2014-02-12 2016-08-10 Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor CL2016002020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1451100A FR3017299B1 (fr) 2014-02-12 2014-02-12 Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur

Publications (1)

Publication Number Publication Date
CL2016002020A1 true CL2016002020A1 (es) 2017-06-23

Family

ID=50729647

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002020A CL2016002020A1 (es) 2014-02-12 2016-08-10 Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor

Country Status (17)

Country Link
US (3) US10046009B2 (enExample)
EP (2) EP3718562A1 (enExample)
JP (1) JP6563958B2 (enExample)
KR (1) KR102354103B1 (enExample)
CN (2) CN106255506B (enExample)
AU (2) AU2015217045B2 (enExample)
BR (1) BR112016017337B1 (enExample)
CA (1) CA2938469C (enExample)
CL (1) CL2016002020A1 (enExample)
ES (1) ES2808849T3 (enExample)
FR (1) FR3017299B1 (enExample)
IL (1) IL246941B (enExample)
JO (1) JO3522B1 (enExample)
MX (1) MX378781B (enExample)
RU (2) RU2744659C2 (enExample)
SG (2) SG10201907367QA (enExample)
WO (1) WO2015121348A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
EA201891606A1 (ru) 2016-01-11 2019-02-28 Эписентарикс, Инк. Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона
RS62939B1 (sr) 2016-01-11 2022-03-31 Rubius Therapeutics Inc Kompozicije i metode u vezi sa multimodalnim terapijskim ćelijskim sistemima u indikacijama kancera
CA3025988A1 (en) 2016-06-02 2017-12-07 Sanofi Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
WO2019010447A1 (en) 2017-07-07 2019-01-10 Epicentrx, Inc. COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF THERAPEUTIC AGENTS
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
JP7176921B2 (ja) 2017-10-19 2022-11-22 アンチキャンサー インコーポレーテッド 癌治療、予防及びアンチエイジングのための組み換えメチオニナーゼを含む製剤
CN111433193A (zh) 2017-12-01 2020-07-17 赛诺菲 药剂和能够结合至葡萄糖传感蛋白的部分的新型缀合物
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020099592A1 (en) 2018-11-15 2020-05-22 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
JP2022530130A (ja) 2019-04-26 2022-06-27 ルビウス セラピューティクス， インコーポレイテッド 除核赤血球細胞を含む緩衝組成物
WO2020243006A1 (en) 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells
CA3159917A1 (en) 2019-11-04 2021-05-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using myo-inositol
WO2021092047A1 (en) 2019-11-04 2021-05-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using taurine or hypotaurine
AU2021270347A1 (en) 2020-05-11 2022-12-15 Erytech Pharma Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
WO2022150569A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF
WO2022150578A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. Methods of treating a tumor in a human subject
WO2022197548A1 (en) 2021-03-14 2022-09-22 Rubius Therapeutics, Inc. Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
TW202313969A (zh) * 2021-05-21 2023-04-01 美商克迪科思股份有限公司 經工程化的甲硫胺酸γ解離酶變異體
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
CN113481253B (zh) * 2021-06-09 2022-05-24 连云港杰瑞药业有限公司 生物催化制备磷酸吡哆醛的方法
WO2023067200A1 (en) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer
WO2025219395A1 (en) 2024-04-16 2025-10-23 Chu D'angers Treatment of cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1354204A (fr) 1963-01-22 1964-03-06 Auxiliaire De L Entpr Soc Dispositif de prévention d'accident pour benne de chargement notamment d'une bétonnière
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5631271A (en) * 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
CA2284111C (en) 1997-03-13 2009-05-19 Shionogi And Co., Ltd. Process for production of l-methionine .gamma.-lyase crystals
US20020111310A1 (en) * 2000-10-06 2002-08-15 Rachel Meyers 25219, a novel human aminotransferase and uses therefor
US20050036981A1 (en) * 2003-07-31 2005-02-17 Shigeo Yagi USE OF PLP WITH PEG-rMETase IN VIVO FOR ENHANCED EFFICACY
FR2873925B1 (fr) * 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
RU2362572C2 (ru) * 2007-07-17 2009-07-27 Юрий Георгиевич Каминский Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
EP2242507B1 (en) 2008-02-13 2013-02-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
CN101429506A (zh) * 2008-12-15 2009-05-13 吉林大学 基于红细胞载体的fish-in-net固定化酶
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
JP5944318B2 (ja) 2009-10-27 2016-07-05 エリテック・ファルマ 特異的免疫寛容を誘導するための組成物
JP6194350B2 (ja) * 2012-03-21 2017-09-06 エリテック・ファルマ 急性骨髄性白血病（ａｍｌ）の処置のための薬剤
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Also Published As

Publication number Publication date
CN106255506B (zh) 2020-04-14
EP3104875B1 (en) 2020-05-06
US10780126B2 (en) 2020-09-22
IL246941B (en) 2019-09-26
IL246941A0 (en) 2016-09-29
US10046009B2 (en) 2018-08-14
RU2019123935A3 (enExample) 2020-03-26
KR102354103B1 (ko) 2022-01-24
RU2697086C2 (ru) 2019-08-12
BR112016017337B1 (pt) 2022-08-09
US20160361361A1 (en) 2016-12-15
JP2017506260A (ja) 2017-03-02
BR112016017337A2 (enExample) 2017-08-08
AU2018201237A1 (en) 2018-03-15
AU2015217045A1 (en) 2016-08-18
RU2016133315A3 (enExample) 2018-09-26
EP3104875A2 (en) 2016-12-21
AU2018201237B2 (en) 2019-09-26
US20210008114A1 (en) 2021-01-14
US20180344771A1 (en) 2018-12-06
JO3522B1 (ar) 2020-07-05
SG11201606264SA (en) 2016-08-30
AU2015217045B2 (en) 2018-03-08
SG10201907367QA (en) 2019-09-27
MX2016010235A (es) 2016-10-28
RU2744659C2 (ru) 2021-03-12
FR3017299A1 (fr) 2015-08-14
MX378781B (es) 2025-03-11
FR3017299B1 (fr) 2018-05-18
CN111358941A (zh) 2020-07-03
CA2938469C (en) 2023-03-14
KR20160121532A (ko) 2016-10-19
RU2019123935A (ru) 2019-10-03
CN111358941B (zh) 2023-12-01
JP6563958B2 (ja) 2019-08-21
RU2016133315A (ru) 2018-02-16
EP3718562A1 (en) 2020-10-07
CA2938469A1 (en) 2015-08-20
WO2015121348A3 (en) 2015-10-08
WO2015121348A2 (en) 2015-08-20
US11458170B2 (en) 2022-10-04
ES2808849T3 (es) 2021-03-02
CN106255506A (zh) 2016-12-21

Similar Documents

Publication Publication Date Title
CL2016002020A1 (es) Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor
EP3447085A4 (en) CELLULOSIC RESIN COMPOSITION AND CELLULOSE COMPONENT
PL3423105T3 (pl) Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania
HUE053619T2 (hu) Anti-CD123 antitestek és konjugátumok és ezek származékai
ES2715251R1 (es) Novedosa composicion farmaceutica que comprende particulas que comprenden un complejo de un polirribonucleotido de doble cadena y una polialquilenimina
EP3500255A4 (en) PHARMACEUTICAL COMPOSITIONS FOR EYE AND RELATED USE
EP3355847A4 (en) ASEPTIC COMPOSITION OF PHARMACEUTICAL CONTAINERS
PT2991511T (pt) Material vaporizável e cápsula
EP3341007A4 (en) MALT1 INHIBITORS AND USES THEREOF
EP3434285A4 (en) PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
BR112017016465A2 (pt) composto heterocíclico e composição farmacêutica que o compreende
EP3463345A4 (en) PHARMACEUTICAL COMBINATIONS
EP3405044A4 (en) BIOKONSERVATION COMPOSITION FOR FOODSTUFFS AND USES THEREOF
BR112016028188A2 (pt) embalagens e método de fabricação da mesma
FI20155027A7 (fi) Polymyksiinijohdannainen ja sen käytöt
PT3320903T (pt) Composição farmacêutica contendo amlodipina, valsartan e rosuvastatina
MA49837A (fr) Compositions pharmaceutiques
PL3145508T3 (pl) Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
EP2994197A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
LT3226905T (lt) Hialuronano konjugatai su farmaciniu požiūriu aktyviomis medžiagomis, būdai ir kompozicijos
FI20145984A7 (fi) Substituoitua bentsofurokinolitsiinia ja ɑ2-adrenergista agonistia käsittävät koostumukset
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
EP3302513A4 (en) COMPOSITION AND USES THEREOF
FI20155009A7 (fi) Pakkausaihio ja pakkaus
EP3302483A4 (en) PHARMACEUTICAL COMPOSITIONS AND USE THEREOF